A Food and Drug Administration advisory panel voted against approval for Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) Duchenne muscular dystrophy treatment eteplirsen sending the stock price plummeting $3.88 to $11.07.
FDA panel votes against approval of Sarepta Therapeutics drug
April 26, 2016 at 12:45 PM EDT